DaVita Inc. (NYSE:DVA), a prominent player in the healthcare sector, specifically within the Zacks Medical - Outpatient and Home Healthcare industry, specializes in providing essential kidney dialysis services for patients with chronic kidney failure. The company's strong market position is reflected in its consistent financial performance and ability to exceed market expectations.
On February 2, 2026, DaVita reported earnings per share (EPS) of $3.40, surpassing the estimated $3.24. This represents a significant improvement from the $2.24 EPS reported in the same quarter the previous year. The earnings surprise for this quarter was +5.08%, highlighting DaVita's ability to outperform market expectations. Over the past four quarters, DaVita has exceeded consensus EPS estimates three times, showcasing its strong financial management.
In terms of revenue, DaVita posted $3.62 billion for the quarter ending December 2025, exceeding the Zacks Consensus Estimate by 2.69%. This is an increase from the $3.29 billion in revenue reported a year ago. The company has consistently outperformed consensus revenue estimates in each of the last four quarters, demonstrating its robust revenue-generating capabilities. This consistent demand for its services has led to a positive outlook for 2026, with projected annual profits expected to surpass estimates.
DaVita's financial metrics further illustrate its market position. The company has a price-to-earnings (P/E) ratio of approximately 10.38, indicating the market's valuation of its earnings. Its price-to-sales ratio stands at about 0.59, suggesting a relatively low market valuation compared to its sales. Additionally, DaVita's enterprise value to sales ratio is around 1.65, while the enterprise value to operating cash flow ratio is approximately 11.63, reflecting the company's cash flow efficiency.
Despite a slight decrease of 0.1% in daily dialysis treatments compared to the third quarter of 2025, DaVita's overall performance remains strong. The company's current ratio of approximately 1.36 suggests a solid ability to cover its short-term liabilities. CEO Javier Rodriguez expressed confidence in DaVita's ability to continue delivering both clinically and financially in 2026 and beyond, thanks to ongoing investments and process improvements.
